AVIR Q4 2023 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$104,000

Operating Income

-$47M

Net Income

-$39M

EPS (Diluted)

$-0.47

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$595M

Total Liabilities

$40M

Stockholders' Equity

$555M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$104,000	-$15M	+99.3%
Operating Income	-$47M	-$40M	-16.7%
Net Income	-$39M	-$34M	-13.7%